Real-world Tactics to Address Health Inequities in Lung Cancer CarePremiere Date: Monday, September 19, 2022
This activity offers CE credit for:%>
- Certified Case Managers (CCMC)
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Dietetic Registration (CDR)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, September 19, 2025
|Edith Peterson Mitchell, MD, MACP, FCPP, FRCP (Moderator)
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
116th President of the National Medical Association
|Ana I. Velázquez Mañana, MD, MSc
Assistant Professor, Division of Hematology Oncology
Zuckerberg San Francisco General Hospital
Assistant Director of Diversity, Equity, Inclusion and Accessibility
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Despite lung cancer being the leading cause of cancer mortality, its survival rate has continued to increase over the past 5 years. However, disparities in early diagnosis, treatment options and access, survival rate, and more remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for lung cancer, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.
In this CME Outfitters BriefCase, a faculty expert will guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with lung cancer. This program will provide actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve lung cancer treatment.
At the end of this CE activity, participants should be able to:
- Recognize the impact of health inequities on patients with lung cancer and develop individual treatment strategies for optimal clinical outcomes
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, PAs, NPs, nurses/nurse navigators, dietitians, pharmacists, specializing in oncology, pathology, radiology, pulmonology, and primary care.
CCMC Credit (Certified Case Managers):
This program has been approved for 0.5 CE credits by the Commission for Case Manager Certification (CCMC).
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning formats: Enduring material
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 0.5 contact hours
Dr. Mitchell reports the following financial relationships:
Advisory Board: Corvus Pharmaceuticals, Inc.
Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.
Dr. Velázquez Mañana reports the following financial relationships:
Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.
Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).